As expected, the highest complete response rates (within each subtype) were seen in the HER2+ (non-luminal) breast cancer subtype (68.8%, n = 11), followed by triple negative (64%, n = 16), luminal B HER2 (59.1%, n = 13) and luminal (26.2%, n = 16), respectively. This evidence concerns the gene ERBB2 and breast carcinoma.